Herbal granules added to standard treatment for extensive-stage small cell lung cancer
Tests a traditional Chinese herbal medicine against placebo in extensive-stage small cell lung cancer.
Key facts
- Who runs it
- LI FENG
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer
- Status
- Not yet recruiting
- People taking part
- 224 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Yishen Qutong Granules
- Yishen Qutong Simulant Granules
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive-stage small cell lung cancer who have not had treatment yet and will start immunotherapy with chemotherapy. A traditional Chinese medicine or a placebo is added.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Extensive-stage small cell lung cancer, confirmed by pathology and imaging, with lesions that can be measured. Also a Traditional Chinese Medicine pattern called Kidney Deficiency and Vital Essence Depletion with Stasis-Toxin Stagnation.
- Earlier treatment
- No earlier Western medical anti-tumor treatment. Plans to receive at least 2 cycles of immunotherapy plus platinum plus etoposide.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Severe diseases of the heart, lung, liver, kidney, blood or other systems
- Taking part in other clinical trials
- History of another primary cancer
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Meets the diagnostic criteria for ES-SCLC by pathology and imaging, as well as the diagnostic criteria of Traditional Chinese Medicine for Kidney Deficiency and Vital Essence Depletion with Stasis-Toxin Stagnation
- No prior Western medical anti-tumor therapy, with evaluable lesions
- Planned to receive at least 2 cycles of immunotherapy + platinum + etoposide regimen
- Age 18 years or older, with an expected survival of ≥3 months
- No history of other prior primary malignancies or malignancy merging
- Karnofsky performance status score ≥ 60
- Normal cognitive function and able to cooperate in completing the questionnaire
- Voluntarily accept the treatment regimen of this study and sign the informed consent form
Who cannot take part
- Pregnant or lactating women, or patients with severe diseases of the heart, lung, liver, kidney, blood, or other systems
- Participants in other clinical trials
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy. Approximately 70% of patients are diagnosed with extensive-stage disease, and only a subset of patients benefit from immunotherapy. Under the leadership of Academician Sun Yan, the principal investigator, our research group previously relied on the Big Data Platform of the National Cancer Center and undertook major projects including those from the National Administration of Traditional Chinese Medicine, the Beijing Administration of Traditional Chinese Medicine for collaborative of major and difficult diseases with integrated traditional Chinese and Western medicine, as well as the National Key R\&D Program. A randomized controlled trial (RCT) of 600 cases demonstrated that the traditional Chinese medicine "Fuzheng Jiedu Huayu" (strengthening vital energy, detoxifying, and resolving stasis) combined with chemotherapy and immunotherapy synergistically improved progression-free survival and disease control rate in patients with extensive-stage SCLC. Building on this foundation, the current project will enroll 224 patients with extensive-stage SCLC (1:1 ratio). On the basis of first-line treatment with immunotherapy plus platinum-based agents and etoposide, patients will be administered either "Fuzheng Jiedu Huayu" traditional Chinese medicine or a placebo. The study will employ objective response rate, progression-free survival, and overall survival as outcome measures, conducting a multicenter, large-sample RCT. Additionally, a multimodal database of no less than 1000 cases will be established, striving to obtain an IND approval, thereby contributing to the realization of the goal set forth in the "Healthy China 2030" Planning Outline: "By 2030, increase the overall 5-year cancer survival rate by 15%."
The 2 groups in the trial
- Treatment group(Yishen Qutong Granules)Treatment being tested
Yishen Qutong Granules administered at 10g per dose, three times daily, in conjunction with immunotherapy plus etoposide and platinum-based first-line treatment.
Treatment: Yishen Qutong Granules
- Control group(Placebo)Placebo, for comparison
In parallel with immunotherapy plus etoposide and platinum-based first-line treatment, administer a simulated formulation of Yishen Qutong Granules (1/10 Yishen Qutong Granules), 10g per dose, three times daily.
Treatment: Yishen Qutong Simulant Granules
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer
- Plain-language title
- Herbal granules added to standard treatment for extensive-stage small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 10 November 2026